Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis

被引:116
作者
Jorgensen, Andrea L. [1 ]
FitzGerald, Richard J. [2 ]
Oyee, James [1 ]
Pirmohamed, Munir [2 ]
Williamson, Paula R. [1 ]
机构
[1] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
关键词
K EPOXIDE REDUCTASE; GAMMA-GLUTAMYL-CARBOXYLASE; ANTICOAGULATION-RELATED OUTCOMES; COMMON GENETIC-VARIANTS; DOSE REQUIREMENTS; CYTOCHROME P4502C9; COMPLEX SUBUNIT-1; INTERINDIVIDUAL VARIABILITY; ORAL ANTICOAGULATION; DOSAGE REQUIREMENTS;
D O I
10.1371/journal.pone.0044064
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Warfarin is a highly effective anticoagulant however its effectiveness relies on maintaining INR in therapeutic range. Finding the correct dose is difficult due to large inter-individual variability. Two genes, CYP2C9 and VKORC1, have been associated with this variability, leading to genotype-guided dosing tables in warfarin labeling. Nonetheless, it remains unclear how genotypic information should be used in practice. Navigating the literature to determine how genotype will influence warfarin response in a particular patient is difficult, due to significant variation in patient ethnicity, outcomes investigated, study design, and methodological rigor. Our systematic review was conducted to enable fair and accurate interpretation of which variants affect which outcomes, in which patients, and to what extent. Methodology/Principal Findings: A comprehensive search strategy was applied and 117 studies included. Primary outcomes were stable dose, time to stable dose and bleeding events. Methodological quality was assessed using criteria of Jorgensen and Williamson and data synthesized in meta-analyses using advanced methods. Pooled effect estimates were significant in most ethnic groups for CYP2C9*3 and stable dose (mutant types requiring between 1.1(0.7-1.5) and 2.3(1.6-3.0) mg/day). Effect estimates were also significant for VKORC1 and stable dose for most ethnicities, although direction differed between asians and non-asians (mutant types requiring between 0.8(0.4-1.3) and 1.5(1.1-1.8) mg/day more in asians and between 1.5(0.7-2.2) and 3.1(2.7-3.6) mg/day less in non-asians). Several studies were excluded due to inadequate data reporting. Assessing study quality highlighted significant variability in methodological rigor. Notably, there was significant evidence of selective reporting, of outcomes and analysis approaches. Conclusions/Significance: Genetic associations with warfarin response vary between ethnicities. In order to achieve unbiased estimates in different populations, a high level of methodological rigor must be maintained and studies should report sufficient data to enable inclusion in meta-analyses. We propose minimum reporting requirements, suggest methodological guidelines and provide recommendations for reducing the risk of selective reporting.
引用
收藏
页数:20
相关论文
共 141 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[3]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[4]   Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].
Aquilante, CL ;
Langaee, TY ;
Lopez, LM ;
Yarandi, HN ;
Tromberg, JS ;
Mohuczy, D ;
Gaston, KL ;
Waddell, CD ;
Chirico, MJ ;
Johnson, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302
[5]   Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment [J].
Bertola, JP ;
Mazoyer, E ;
Bergmann, JF ;
Drouet, L ;
Simoneau, G ;
Mahé, I .
THROMBOSIS RESEARCH, 2003, 109 (5-6) :287-291
[6]  
Blackshear JL, 1996, LANCET, V348, P633
[7]   Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans [J].
Bodin, L. ;
Perdu, J. ;
Diry, M. ;
Horellou, M. -H. ;
Loriot, M. -A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) :1436-1439
[8]   CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population [J].
Borgiani, P. ;
Ciccacci, C. ;
Forte, V. ;
Sirianni, E. ;
Novelli, L. ;
Bramanti, P. ;
Novelli, G. .
PHARMACOGENOMICS, 2009, 10 (02) :261-266
[9]   Management of narrow therapeutic index drugs [J].
Burns, M .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1999, 7 (02) :137-143
[10]   CYP4F2 genetic variant alters required warfarin dose [J].
Caldwell, Michael D. ;
Awad, Tarif ;
Johnson, Julie A. ;
Gage, Brian F. ;
Falkowski, Mat ;
Gardina, Paul ;
Hubbard, Jason ;
Turpaz, Yaron ;
Langaee, Taimour Y. ;
Eby, Charles ;
King, Cristi R. ;
Brower, Amy ;
Schmelzer, John R. ;
Glurich, Ingrid ;
Vidaillet, Humberto J. ;
Yale, Steven H. ;
Zhang, Kai Qi ;
Berg, Richard L. ;
Burmester, James K. .
BLOOD, 2008, 111 (08) :4106-4112